Culture filtrate proteins from BCG act as adjuvants for cytotoxic T lymphocyte induction

Front Immunol. 2023 Oct 18:14:1271228. doi: 10.3389/fimmu.2023.1271228. eCollection 2023.

Abstract

Mycobacterium bovis bacilli Calmette-Guerin (BCG) is a licensed vaccine against tuberculosis. It requires attenuated live bacteria to be effective, possibly because actively secreted proteins play a critical role in inducing anti-tuberculosis immunity. BCG also functions as an effective adjuvant. Moreover, the effects of BCG components as adjuvants are not important as those of attenuated live BCG, which is used in cancer immunotherapy. However, the BCG secreted proteins have not been paid attention in anticancer immunity. To understand mycobacterial secreted proteins' function, we investigate immune responses to BCG culture filtrate proteins (CFP). Here, CFP strongly induce both antigen-specific CD4+ T cells and specific CD8+ T cells, which may be functional cytotoxic T lymphocytes (CTLs). In this study, we clearly demonstrate that CFP acts as an adjuvant for CTL induction against specific co-administered proteins and propose CFP as a new protein adjuvant. The CTL response shows potent anticancer effects in mice. These findings could provide insight into the contribution of mycobacterial secreted proteins in both anticancer and antimycobacterial immunity.

Keywords: Mycobacterium bovis bacilli Calmette-Guerin; culture filtrate protein; cytotoxic T lymphocytes; immunotherapy; tuberculosis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adjuvants, Immunologic / pharmacology
  • Animals
  • BCG Vaccine
  • CD8-Positive T-Lymphocytes
  • Mice
  • Mycobacterium bovis*
  • T-Lymphocytes, Cytotoxic
  • Tuberculosis*

Substances

  • BCG Vaccine
  • Adjuvants, Immunologic

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was partly supported by the Japan Agency for Medical Research and Development (AMED) under Grant number JP223fa627005.